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A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive 
cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg), and 
eventually recovered. His initial serum contained genotype IA hepatitis A virus (HAV), which was subsequently replaced 
by genotype IIIA HAV. Moreover, at the time of development of hemolytic anemia, he became positive for immunoglobulin 
M (IgM) anti-hepatitis E virus (HEV). We detected HAV antigens in the liver biopsy specimen, while we detected neither 
HEV antigen in the liver nor HEV RNA in his serum. This is the first report of hepatitis A coinfected with two different 
genotypes manifesting with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive IgM anti-HEV. 
(Korean J Hepatol 2011;17:323-327)
Keywords: Hepatitis A virus; Genotype; Coinfection; Hemolytic anemia; Korea
Received November 8, 2010; Revised July 12, 2011; Accepted July 26, 2011
Abbreviations: AIHA, autoimmune hemolytic anemia; anti-IgG, immunoglobulin G antibody; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; HAV, Hepatitis A virus; Hb, hemoglobin; HCV, Hepatitis C virus; HEV, Hepatitis E virus; HAV RNA, hepatitis A virus 
ribonucleic acid; HEV RNA, hepatitis E virus ribonucleic acid; IgM anti-HAV, immunoglobulin M antibody to hepatitis A virus; IgM anti-HBc,
immunoglobulin M antibody to hepatitis B core antigen; IgM anti-HEV, immunoglobulin M antibody to hepatitis E virus; INR, international 
normalized ratio; γ-GT, gamma-glutamyl transpeptidase
Corresponding author: Sook-Hyang Jeong
Department of Internal Medicine, Seoul National University Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam 463-707, Korea
Tel. +82-31-787-7039, Fax. +82-31-787-7042, E-mail; jsh@snubh.org
Copyright Ⓒ  2011  by  The Korean Association for the Study of the Liver
The Korean Journal of Hepatology∙pISSN: 1738-222X eISSN: 2093-8047
INTRODUCTION
Hepatitis A virus (HAV) remains an important causative 
agent of acute viral hepatitis, causing large outbreak or severe 
cases of fulminant hepatitis with fatal outcomes. Acute 
hepatitis A can be complicated by extrahepatic manifestations, 
including hemolytic anemia, aplastic anemia, acute renal 
failure, and acute reactive arthritis.
1,2
Although HAV displays only a single serotype, seven HAV 
genotypes have been identified: four genotypes (I, II, III and 
VII) are of human origin, and other three (IV, V, VI) are of 
simian origin. HAV genotypes have unique geographic 
distributions; however, co-circulation of multiple genotypes 
or subgenotypes has been reported in some regions of 
world.
3 
This report presents a peculiar coinfection hepatitis with 
the HAV genotype IA and IIIA, complicated by severe 
autoimmune hemolytic anemia and prolonged cholestasis, 
along with coexistence of IgM anti-hepatitis E virus (HEV). 
We performed immunohistochemical staining of HAV antigen 
and HEV antigen in the liver biopsy specimen, and 
molecular detection of HAV RNA and HEV RNA in the 
serial serum samples obtained from the patient. 324  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 1. Hematologic and biochemical findings of the case
2008/12/28 2009/1/6 2009/1/12 2009/1/19 2009/1/24
* 2009/2/12
† 2009/2/20
‡ 2009/4/22
Hemoglobin, g/dL
Reticulocyte, %
Total bilirubin, mg/dL
AST, IU/L
ALT, IU/L
γ-GT, IU/L
Albumin, g/dL
Prothrombin time, INR
HAV RNA 
  in plasma
  in stool
HEV RNA  
  in plasma
  in stool
14.3
4.5
>12000
8129
349
3.7
1.69
14.4
21.8
285
919
448
3.2
1.06
11.2
34.2
79
138
350
3.6
1.04
IA
IA
ND
ND
7.6
0.13
37.8
76
88
325
3.0
1.03
5.5
0.31
39.3
154
130
552
3.1
1.08
IA
IA
10
7.49
10
90
380
1482
3.8
0.90
ND
ND
ND
ND
12.1
2.22
5.4
22
136
897
3.8
0.90
14.3
0.7
21
49
3.8
IIIA
ND
ND, not detected.
* Prednisolone 75 mg per day started on this day, 
† Liver biopsy was performed during therapy with prednisolone 105 mg per day, 
‡ Discharge day on prednisolone 75 mg per day administration.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HAV, Hepatitis A virus; HEV, Hepatitis E virus; ND, not detected.
CASE REPORT
A 37-year-old male visited the emergency room on 
December 28, 2008 for treatment of fever (40℃), chills, and 
jaundice lasting for 2 days. He was a nonsmoking social 
drinker, and denied recent overseas travel, contact with 
hepatitis cases, or taking any medications. His past medical 
history revealed an episode of pneumonia and bronchiectasis 
that occurred 20 years earlier. Physical examination showed 
a temperature of 40℃ and mild icterus without hepatosplenomegly. 
Results from chest and throat examination were normal 
without cervical lymphadenopathy. His initial level of 
aspartate transaminase (AST) was 12,000 IU/L, alanine 
aminotransferase (ALT) 8,129 IU/L, total bilirubin 4.5 mg/dL, 
prothrombin time 23.6 second (international normalized 
ratio 2.06) and hemoglobin (Hb) 14.3 g/dL. IgM anti-HAV 
(Microparticle Enzyme immunoassay, Abbott, Wiesbaden, 
Germany) and IgG anti-HAV (Radio-immunoassay kit, 
General Biologicals corp., Taiwan) were both positive. 
Hepatitis B virus surface antigen, IgM anti-HBc, hepatitis C 
virus (HCV) RNA, and anti-HCV were all negative. IgM 
anti-HEV (Genelabs Diganostics, Singapore) was negative. 
Chest X ray and CT scan of the abdomen and chest showed 
no remarkable findings. Under diagnosis of acute hepatitis 
A, the patient received supportive care showing gradual 
recovery, and AST/ALT levels decreased to 285/919 IU/L, 
with a stable hemoglobin level of 14.4 g/dL, while his total 
bilirubin level progressively increased up to 21.8 mg/dL at 
hospital discharge (January 6, 2009) suggesting a prolonged 
cholestatic feature. 
On January 12, 2009, he was readmitted for recurrent 
fever, general weakness, and aggravated jaundice. At this 
time, IgM anti-HEV was positive with persistently positive 
IgM anti-HAV. Total and direct bilirubin levels were 39 mg/dL 
and 29 mg/dL, respectively, with an alkaline phosphatase 
level of 374 IU/L, and Hb level was 13.4 g/dL. Until January 
24, total bilirubin level increased rapidly, up to 64.1 mg/dL 
(direct bilirubin level of 41 mg/dL), and Hb level fell rapidly 
to 5.5 g/dL, despite decreasing levels of transaminase. Serial 
laboratory results are summarized in Table 1. Haptoglobin 
level was 27.3 mg/dL and direct Coombs' test was positive 
(anti-IgG type) with polychromasia and anisocytosis on a 
blood film (Fig. 1A), which was compatible with autoimmune 
hemolytic anemia (AIHA). IgM anti-parvovirus B19 was 
negative.
Oral prednisolone therapy (1 mg/kg) was started on 
January 22, however, his reticulocyte count remained low 
(0.13%), and he received 17 units of red blood cell 
transfusion for 11 days. To exclude the possibility of pure 
red cell aplasia, bone marrow aspiration and biopsy were 
performed, and it showed increased erythropoiesis compatible 
with AIHA without evidence of pure red cell aplasia 
(Fig. 1B). The dosage of oral prednisolone therapy was 
incremented to 1.5 mg/kg/day, and after 8 days of the Hee-Sup Kim, et al. Coinfection hepatitis A genotype IA and IIIA  325
A B
Figure 1. (A) Peripheral blood smear showing marked polychromasia and anisocytosis (Wright-Giemsa stain, ×1,000). (B) Photomicrographs 
of a bone marrow biopsy section showing increased erythropoiesis [hematoxylin and eosin stain (H&E), ×400].
A B
Figure 2. The liver biopsy specimen exhibited hepatocellular and canalicular cholestasis, hepatocyte ballooning, and lobular spotty 
necrosis, consistent with cholestatic hepatitis. Extramedullary hematopoiesis was also seen (arrow; H&E, ×200). 
A B
Figure 3. Immunohistochemical staining of the liver biopsy specimen. Strong cytoplasmic staining for hepatitis A virus antigen was 
noted in our case (A), whereas staining was absent in a case of chronic hepatitis B (B) as a negative control (A and B, ×400).326  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
incremental dose therapy, the patient became gradually 
transfusion-independent with increase of Hb level to 12.1 
g/dL. Liver function tests showed AST of 22 IU/L, ALT 136 
IU/L, alkaline phosphatase 285 IU/L, gamma-glutamyl 
transferase (GGT) 897 IU/L, and total bilirubin of 5.4 mg/dL.
To exclude the possibility of fibrosing cholestatic hepatitis 
associated with immunosuppressive therapy, percutaneous 
liver biopsy was undertaken on February 12, which revealed 
hepatocellular and canalicular cholestasis, hepatocyte 
ballooning, and lobular spotty necrosis compatible with 
cholestatic hepatitis and extramedullary hematopoiesis 
(Fig. 2). Immunohistochemical staining was performed for 
detection of HAV antigens and HEV antigens using HAV 
antibody (Purified HAV, Abcam, Cambridge, UK; mouse 
monoclonal, 1:50) and HEV antibody (Abbiotec, CA, USA; 
1:200), respectively. Strong cytoplasmic staining for HAV 
was noted, whereas staining was absent in specimens used 
for negative control (Fig. 3). In this case, there was no staining 
for HEV antigen (data not shown). 
After a 2 month-period of gradual tapering of prednisolone, 
complete recovery of liver function was achieved at 5 months 
after the patient’s initial admission. However, his IgM 
anti-HAV was positive until May 29, while both IgM anti- 
HEV and IgG anti-HEV (Genelabs Diganostics, Singapore) 
were negative. 
During the course of his illness, serial serum samples 
were available for detection of HAV RNA and HEV RNA, 
according to the method described in previous studies.
4 All 
HAV RNA-positive samples were sequenced using the 
BigDye Terminator (ABI Prism 377 automatic sequencer, 
Toroed, Norway). Interestingly, initial HAV detected on 
January 14, 2009 was genotype IA, which was subsequently 
replaced by HAV genotype IIIA during the later phase of the 
illness (April 22, 2009), while HEV RNA was not detected 
by Okamoto’s method, as previously reported.
5,6
DISCUSSION
This report described a case of acute viral hepatitis coinfected 
by HAV genotype IA and genotype IIIA complicated with 
severe autoimmune hemolytic anemia, prolonged cholestasis, 
and coexistence of IgM anti-HEV, which was successfully 
treated by high dose (1.5 mg/kg/day) prednisolone therapy. 
There have been a few reports of severe Coombs-positive 
AIHA with or without pure red cell aplasia, complicating acute 
viral hepatitis.
7 However, coinfection of HAV genotype IA 
and IIIA complicated with severe AIHA has not been 
reported. Genotype 1A HAV was a major genotype in Korea, 
however, during recent nationwide outbreak of hepatitis A, a 
rapid genotypic shift from genotype IA to IIIA has occurred.
4,8 
Therefore, at least two genotypes of HAV co-circulate in 
Korea.
Coinfection of the HAV genotype IA and IIIA was a 
peculiar finding in this case. From onset of symptoms to 
development of AIHA, HAV genotype IA was consistently 
detected in the patient’s plasma and stool. Subsequently, 
during prolonged follow-up, his HAV genotype was replaced 
from genotype IA to IIIA. This replacement can be explained 
by initially mixed infection of HAV genotype IA and IIIA 
with a dominant population of HAV genotype IA and reciprocal 
inhibition of genotype IIIA. During his initial hepatitis 
course, vigorous immune responses may have controlled 
HAV genotype IA up to an undetectable level, and subsequent 
strong immunosuppression for the treatment of hemolytic 
anemia may support replication of HAV genotype IIIA, a 
minor population. To our knowledge, this is the first case of 
coinfection of hepatitis A genotype IA and IIIA documented. 
Coppola et al
9 reported a case of acute hepatitis A 
complicated with prolonged cholestasis and coinfection of 
genotype IA and IB, and suggested that coinfection of two 
HAV subgenotypes may be a reason for prolonged cholestasis 
and viremia due to impairment of antibody production or 
neutralizing activity on the basis of the simultaneous antigenic 
stimulatory effect of the two HAV isolates. However, HAV 
has only one common serotype, and this finding was not 
supported by experimental data.
The interesting finding of this case was that IgM anti- 
HEV at the first manifestation was negative, which turned 
out to be positive at the initiation of hemolytic anemia. 
Afterwards, the transiently positive result for IgM anti-HEV 
turned out to be negative, along with a negative result for 
IgG anti-HEV during the follow-up period. Both hepatitis A 
virus (HAV) and hepatitis E virus (HEV) infection can be 
transmitted by the fecal-oral route with similar incubation 
periods and clinical presentations. Among patients with 
sporadic acute viral hepatitis, cases showing simultaneously 
positive results for immunoglobulin M (IgM) anti-HAV and 
IgM anti-HEV have been reported, and were regarded as 
coinfection of HAV and HEV.
10,11 However, HEV RNA was 
not detected in serum and stool samples, while HAV RNA Hee-Sup Kim, et al. Coinfection hepatitis A genotype IA and IIIA  327
was detected and genotyped. In immunohistochemical 
staining of liver biopsy specimens, HAV antigens showed 
strongly positive staining, in contrast to no staining for HEV 
antigens, although we were not able to obtain adequate 
positive control specimens. All of these results suggested the 
false positive reaction of initially positive IgM anti-HEV, 
rather than a true coinfection of HEV along with HAV.
12 
Severe cell necrosis associated with HAV infection may 
induce autoimmune reaction such as hemolytic anemia or 
autoimmune hepatitis.
13,14 Nonspecific induction of IgM 
anti-HEV during massive hepatic necrosis death in the 
hepatitis phase of this case may be a possibility. 
In conclusion, severe autoimmune hemolytic anemia and 
prolonged cholestasis can be complicated with acute hepatitis 
co-infected by HAV genotype IA and IIIA, which was 
successfully treated with high-dose prednisolone therapy. 
The coexistence of IgM anti-HEV in the setting of hepatitis 
A seems to be a false positive reaction rather than a true 
coinfection.
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